Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag Teva- Pharmaceutical Industries Ltd. 3/07 17,010 USD
-0,23% 		-0,23%
vlag TherapeuticsMD Inc 3/07 1,180 USD
+3,51% 		+3,51%

Nieuws over “Farmaceutische Producten: Generisch”

26/06 · Teva Releases Q2 2025 Aide Memoire · Persbericht

26/06 · Teva Releases Q2 2025 Aide Memoire · Persbericht

25/06 · Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 · Persbericht

23/06 · Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine · Persbericht

16/06 · Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology · Persbericht

3/06 · Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer · Persbericht

3/06 · Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement · Persbericht

31/05 · New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 · Persbericht

31/05 · Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date · Persbericht

29/05 · Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day · Persbericht

28/05 · Form 8.3 - [BENCHMARK HOLDINGS PLC - Opening Disclosure - 23 05 2025] - (CGAML) · Persbericht

27/05 · Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA · Persbericht

27/05 · Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June · Persbericht

27/05 · Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma · Persbericht

22/05 · Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes · Persbericht

20/05 · Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt · Persbericht

20/05 · Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy · Persbericht

19/05 · Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031 · Persbericht

19/05 · Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes · Persbericht

16/05 · Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy · Persbericht

12/05 · Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy · Persbericht

Mijn selecties